Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 8/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 8/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20739933 | 0.81 | PIM1 (0.38) | L3MBTL1CARM1PRMT6PIM1GNAI3 | |
| SCHEMBL27317530 | 0.79 | CARM1 (0.64) | L3MBTL1CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL23945810 | 0.79 | L3MBTL1 (0.57) | L3MBTL1CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL13744813 | 0.79 | PIM1 (0.36) | PIM1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL23181937 | 0.78 | GSK3B (0.43) | HTR4GSK3B | |
| SCHEMBL22851678 | 0.77 | PIM1 (0.36) | L3MBTL1CARM1PRMT6PIM1GNAI3 | |
| SCHEMBL22544374 | 0.77 | L3MBTL1 (0.51) | L3MBTL1CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL24172131 | 0.77 | PIM1 (0.36) | CARM1PRMT6PRMT8PRMT1PIM1 | |
| SCHEMBL2250676 | 0.77 | CARM1 (0.38) | CARM1PRMT6PRMT8PRMT1PIM1 | |
| SCHEMBL14174933 | 0.76 | GNAO1 (0.42) | PIM1GNAI3GNAO1GNAI1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393647-A9 | ACETAMIDE THIENOTRIAZOLODIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210093644-A1 | ACETAMIDE THIENOTRIAZOLODIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10881668-B2 | Acetamide thienotriazolodiazepines and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| WO-2019165229-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190046541-A1 | ACETAMIDE THIENOTRIAZOLODIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-14 | — | — | US | disclosed |
| WO-2017044792-A1 | ACETAMIDE THIENOTRIAZOLDIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046541-A1 | ACETAMIDE THIENOTRIAZOLODIAZEPINES AND USES THEREOF | BRDT, BRD4, BRD3 | L3MBTL1 3238/4885CARM1 948/4885PRMT6 1204/4885 |
| US-20210093644-A1 | ACETAMIDE THIENOTRIAZOLODIAZEPINES AND USES THEREOF | BRDT, BRD4, BRD3 | L3MBTL1 3284/4885CARM1 960/4885PRMT6 1275/4885 |
| US-10881668-B2 | Acetamide thienotriazolodiazepines and uses thereof | BRDT, BRD4, BRD3 | L3MBTL1 3238/4885CARM1 948/4885PRMT6 1204/4885 |
| US-20210393647-A9 | ACETAMIDE THIENOTRIAZOLODIAZEPINES AND USES THEREOF | BRDT, BRD4, BRD3 | L3MBTL1 3284/4885CARM1 960/4885PRMT6 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.